GlassScriptPhysician profile
David L Hykes
NPI 1992763155
$4,316.37
in general payments reported to CMS, 2019-2025
25 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $807 · 2021: $1,057 · 2022: $979 · 2023: $246 · 2024: $46.35 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.65 | 2019-2023 | |
| Janssen Biotech, INC. | $596.53 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $593.43 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $536.75 | 2019-2024 | Xifaxan |
| Pfizer INC. | $269.89 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $132.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.08 | 2023 | Zeposia |
| Gilead Sciences, INC. | $95.07 | 2020-2021 | |
| Medtronic, INC. | $89.86 | 2023 | Eea |
| Nestle Healthcare Nutrition INC. | $88.68 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $59.45 | 2019-2022 | |
| Concordia Pharmaceuticals INC. | $58.04 | 2019 | |
| Merck Sharp & Dohme LLC | $56.78 | 2021-2023 | Dificid |
| Braintree Laboratories, INC. | $52.90 | 2019-2020 | |
| Olympus America INC. | $50.65 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50.39 | 2022 | |
| Shionogi INC | $45.95 | 2019-2020 | |
| Ucb, INC. | $37.65 | 2019-2020 | |
| Celgene Corporation | $31.15 | 2022 | |
| Vivus LLC | $29.73 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $22.22 | 2022 | |
| Csl Behring | $18.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.59 | 2019 | |
| Ardelyx, INC. | $14.83 | 2022 | |
| Allergan, INC. | $14.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hykes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.